Last reviewed · How we verify
NCT05190237
the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement.
NA trial testing TMD21-16 group in Immunity in 45 participants. Completed in 7 February 2022.
24 December 2021
Quick facts
| Lead sponsor | Chonbuk National University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 45 |
| Start date | 19 November 2021 |
| Primary completion | 24 December 2021 |
| Estimated completion | 7 February 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- TMD21-16 group
- TCD21-55 group
- TFD21-1 group
Conditions studied
- Immunity — all drugs for Immunity →
Sponsor
Chonbuk National University Hospital
Who can join
Adults 19 to 75, any sex, with Immunity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted to investigate the efficacy and safety of Fermented soybean(Doenjang powder) on intestinal microflora and immune enhancement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05190237
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunity
Currently open trials in the same condition.
- NCT07341750 — Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children · NA · recruiting
- NCT06724185 — Effects of LP28 on Immunity Enhancement in the Elderly · NA · recruiting
Other Chonbuk National University Hospital trials
Trials by the same sponsor.
- NCT05324800 — the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement · NA · unknown
- NCT05450939 — Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture · unknown
- NCT05495191 — Signal Intensity Gradient in Cerebral Arteries · completed
- NCT04940910 — The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement · NA · unknown
- NCT04930640 — The Efficacy and Safety of SGF200 on Immune Enhancement · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05190237 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chonbuk National University Hospital
- Last refreshed: 16 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05190237.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing